Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist
Contact+90 (538) 677 60 18

Idelalisib

ContributorsAuthor
Published
Updated
1 min read
Idelalisib

Approved by the FDA on 23 July 2014, Zydelig began being used for recurrent Non-Hodgkin Lymphoma, one type of recurrent leukemia, and recurrent Chronic Lymphocytic Leukemia in combination treatment. It acts by suppressing PI3K (phosphoinositide 3 kinase), a small molecule that can cause blood cancers, through intracellular pathways.

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Idelalisib

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy